NY-ESO-1c259T + chemotherapy

NY-ESO-1c259T + chemotherapy is a combination therapy consisting of genetically engineered autologous T cells—NY-ESO-1c259T—that express an affinity-enhanced T-cell receptor targeting the NY-ESO-1 cancer/testis antigen, administered in conjunction with preparative chemotherapy. NY-ESO-1c259T are manufactured by collecting T cells from the patient, genetically modifying them with an engineered T-cell receptor specific for NY-ESO-1 presented by HLA-A*02 molecules, expanding them, and reinfusing them after lymphodepleting chemotherapy. The preparative chemotherapy is used to deplete existing immune cells and facilitate engraftment of the engineered T cells. This therapy is designed to direct cytotoxic immune responses specifically toward NY-ESO-1-expressing tumor cells. NY-ESO-1 is highly immunogenic and restricted largely to germ cells and a variety of solid tumors (notably synovial sarcoma, myxoid/round cell liposarcoma, NSCLC, and melanoma), with little or no expression in normal adult tissues, making it an attractive immunotherapy target. The combination is under investigation for advanced solid tumors, especially NY-ESO-1–positive cancers, and has demonstrated partial responses in phase I/II studies of sarcomas and NSCLC. The NY-ESO-1c259T component is a T cell receptor engineered T cell therapy developed by Adaptimmune, often used alongside lymphodepleting chemotherapies such as fludarabine and cyclophosphamide[1][3][7][8].